CD14 and myeloid sarcoma: Conversely, BCD and FTY therapy resulted in a higher proportion of granulocytes (C1 and C2, Fig. 1D) and CD14+CD16- monocytes (C8 and C9) were increased in FTY- and IFNβ-treated MS patients (Fig. 1D).